CVS Health reported fourth-quarter earnings that exceeded analyst expectations, with adjusted EPS of $1.09 beating estimates by 9 cents. Revenue climbed 8.2% to $105.7 billion, surpassing consensus forecasts of $103.63 billion. The healthcare giant's shares fell 2.5% premarket despite the positive results.

For the full year, CVS delivered record revenues of $402.1 billion, up 7.8% year-over-year, with adjusted EPS of $6.75 representing a 24.5% increase. The Pharmacy & Consumer Wellness segment showed particularly strong performance, with revenue increasing 12.4% in the fourth quarter driven by higher prescription volume and favorable pharmacy drug mix.

However, the company lowered its 2026 cash flow from operations guidance to at least $9.0 billion from the previous target of $10.0 billion, raising concerns among investors. CVS maintained its full-year 2026 adjusted EPS guidance range of $7.00 to $7.20, which aligns with analyst expectations of $7.17. CEO David Joyner emphasized the company's progress in transforming healthcare delivery while navigating industry headwinds.